32.11
Precedente Chiudi:
$32.02
Aprire:
$32.1
Volume 24 ore:
17,982
Relative Volume:
0.04
Capitalizzazione di mercato:
$1.80B
Reddito:
$345.60M
Utile/perdita netta:
$-79.01M
Rapporto P/E:
-20.01
EPS:
-1.6045
Flusso di cassa netto:
$-18.62M
1 W Prestazione:
+2.62%
1M Prestazione:
+0.37%
6M Prestazione:
+10.21%
1 anno Prestazione:
-4.80%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Nome
Immunocore Holdings Plc Adr
Settore
Industria
Telefono
01235 5430281
Indirizzo
90 PARK DRIVE, OXFORDSHIRE
Confronta IMCR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
IMCR
Immunocore Holdings Plc Adr
|
32.20 | 1.80B | 345.60M | -79.01M | -18.62M | -1.6045 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.24 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
528.15 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
317.97 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
562.75 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
243.73 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-27 | Iniziato | Deutsche Bank | Buy |
2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-11-11 | Downgrade | Mizuho | Outperform → Neutral |
2024-10-24 | Iniziato | UBS | Sell |
2024-10-07 | Downgrade | Guggenheim | Buy → Neutral |
2024-04-29 | Iniziato | Leerink Partners | Outperform |
2023-11-20 | Ripresa | JP Morgan | Overweight |
2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
2023-10-31 | Iniziato | Robert W. Baird | Outperform |
2023-09-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-09-13 | Iniziato | Needham | Buy |
2023-08-16 | Iniziato | CapitalOne | Overweight |
2023-07-17 | Iniziato | Canaccord Genuity | Hold |
2023-03-31 | Iniziato | Mizuho | Buy |
2023-03-30 | Iniziato | Guggenheim | Buy |
2023-03-24 | Iniziato | Bryan Garnier | Buy |
2022-12-16 | Aggiornamento | Goldman | Neutral → Buy |
2022-11-30 | Iniziato | Barclays | Overweight |
2022-09-09 | Iniziato | Morgan Stanley | Overweight |
2022-09-08 | Iniziato | Ladenburg Thalmann | Buy |
2022-08-08 | Iniziato | Cowen | Outperform |
2022-08-02 | Iniziato | BTIG Research | Buy |
2022-02-08 | Iniziato | H.C. Wainwright | Buy |
2021-10-20 | Iniziato | Oppenheimer | Outperform |
2021-03-02 | Iniziato | Goldman | Neutral |
2021-03-02 | Iniziato | JP Morgan | Overweight |
2021-03-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunocore Holdings Plc Adr Borsa (IMCR) Ultime notizie
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings Plc Adr Azioni (IMCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):